Pet Pharm Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	222.03	130.7	117.87	75.74
Revenue Growth (YoY)	69.88%	10.89%	55.62%	-
Cost of Revenue	105.59	60.74	53.27	39.88
Gross Profit	116.44	69.96	64.59	35.86
Selling, General & Admin	91.69	49.74	44.16	31.71
Research & Development	10	12.14	14.05	7.79
Operating Expenses	101.7	61.85	57.01	40.7
Operating Income	14.74	8.11	7.59	-4.84
Interest Expense	-0.89	-0.18	-0.18	-0.2
Interest & Investment Income	6.79	4.1	1.67	0.45
Currency Exchange Gain (Loss)	-	0.23	0.06	-
Other Non Operating Income (Expenses)	3.54	0.15	0.01	0.77
Pretax Income	24.17	12.42	9.15	-3.81
Income Tax Expense	-0.72	-2.09	-	-
Earnings From Continuing Operations	24.9	14.51	9.15	-3.81
Minority Interest in Earnings	0.09	-	-	-
Net Income	24.99	14.51	9.15	-3.81
Net Income to Common	24.99	14.51	9.15	-3.81
Net Income Growth	72.25%	58.54%	-	-
Shares Outstanding (Basic)	54	41	30	24
Shares Outstanding (Diluted)	54	41	30	24
Shares Change (YoY)	33.15%	37.23%	23.19%	-
EPS (Basic)	0.46	0.36	0.31	-0.16
EPS (Diluted)	0.46	0.36	0.31	-0.16
EPS Growth	29.50%	16.12%	-	-
Free Cash Flow	4.79	-159.51	8.08	-27.87
Free Cash Flow Per Share	0.09	-3.91	0.27	-1.16
Dividend Per Share	-	0.088	0.197	-
Dividend Growth	-	-55.27%	-	-
Gross Margin	52.44%	53.53%	54.80%	47.34%
Operating Margin	6.64%	6.21%	6.44%	-6.39%
Profit Margin	11.25%	11.10%	7.76%	-5.03%
Free Cash Flow Margin	2.16%	-122.05%	6.85%	-36.80%
EBITDA	49.33	19.45	18.75	9.46
EBITDA Margin	22.22%	14.88%	15.91%	12.49%
D&A For EBITDA	34.58	11.34	11.17	14.3
EBIT	14.74	8.11	7.59	-4.84
EBIT Margin	6.64%	6.21%	6.44%	-6.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.